01 / Research

Filing-backed research notes

Daily analysis of Indian market events grounded in real corporate filings. Every claim is backed by what companies actually said in their annual reports and quarterly results.


Impact Analysis 17 April 2026

Aluminium at $4,000 a Tonne? Here Are the Indian Companies With the Most to Gain

With LME aluminium prices forecast to hit $4,000/tonne on Russia sanctions and supply tightening, we dig into the filings of Hindalco, Vedanta, and three downstream players to see who benefits most.

HINDALCOVEDLCENTEXTMAANALUMMP
Policy Impact 16 April 2026

Mobile PLI 2.0 Is Coming in May — Here's Who's Best Positioned to Win Round Two

With Mobile PLI 2.0 expected to roll out in May 2026 at over $5B outlay, filings point to Dixon (Rs 10,919 Cr mobile revenue, 60% market share), Optiemus (PLI-selected subsidiaries), Kaynes, Cyient DLM, Amber, and EPACK as the best-positioned beneficiaries.

DIXONOPTIEMUSKAYNESCYIENTDLMAMBEREPACK
Policy Impact 15 April 2026

India Offers Zero Tariffs on Steel and Auto Parts to the US — Five Companies Already in Position

India's proposed zero-for-zero tariff deal with the US on steel and auto components could unlock significant export growth. We dig into filings of JSW Steel, Jindal Steel, Motherson, Happy Forgings, and Subros to find who benefits most.

JSWSTEELJINDALSTELMOTHERSONHAPPYFORGESUBROS
Policy Impact 14 April 2026

Delhi's Draft EV Policy Could Reshape Two-Wheeler Markets — Here Are the Winners and Losers

Delhi proposes phasing out petrol two-wheelers and offering Rs 1 lakh scrappage incentives. We dig into company filings to find which EV makers stand to gain and which ICE-dependent firms face risk.

ATHERENERGBAJAJ-AUTOOLECTRAHEROMOTOCOEICHERMOTJBMA
Policy Impact 13 April 2026

India-UK Free Trade Deal Goes Live in May — 5 Exporters Positioned to Gain

The India-UK FTA takes effect in May 2026 with tariff cuts across sectors. We dug into filings to find which Indian exporters have the most UK revenue at stake.

DRREDDYWELSPUNLIVKPRMILLPDSLTATAMOTORSRADICO
Impact Analysis 10 April 2026

West Asia Crisis Squeezes India's Pharma Supply Chain: Who Gets Hurt and Who's Prepared

The Israel-Iran conflict is disrupting key solvent and feedstock supplies for Indian pharma companies. We dig into filings to find which companies face margin pressure and which are better positioned.

CIPLASUNPHARMAGLANDCOHANCEJUBLPHARMAMANKINDCAPLIPOINT
Sector Insight 9 April 2026

AERA Just Cut Airport Charges by 25% — The Real Winners Aren't Who You'd Expect

AERA ordered Indian airports to cut some charges 25%. GMR Airports and Adani Enterprises take the hit, but IndiGo's ₹5,753 crore airport fees line means airlines are the hidden winner.

GMRAIRPORTINDIGOADANIENT
Policy Impact 8 April 2026

India Just Restricted Gold Jewellery Imports — 4 Domestic Jewellers Positioned to Benefit

India moved gold and silver jewellery imports into the restricted category. Filing evidence shows Titan, MVGJL, Motisons and Sky Gold as structural beneficiaries of the policy tilt toward domestic, branded supply.

TITANMVGJLMOTISONSSKYGOLD
Opportunity 6 April 2026

Trump Slaps 100% Tariff on Patented Drugs — Why Indian Generic Makers Could Be the Biggest Winners

The US 100% tariff on patented drug imports targets Big Pharma, not Indian generics. Here are 5 NSE-listed companies whose filings show they are positioned to benefit as American buyers accelerate the switch to off-patent alternatives.

SUNPHARMADRREDDYCIPLAAUROPHARMAALKEM
Policy Impact 3 April 2026

India Waives Customs Duty on Petrochemicals: 5 Stocks That Stand to Gain

The government has exempted customs duty on critical petrochemical products till June 30 amid the West Asia crisis. Here are five NSE-listed companies whose margins could improve.

FILATEXPOLYPLEXDEEPAKNTRSTYRENIXAPOLLOTYRE
Deep Dive 2 April 2026

Everyone's Watching the War — But China's Biologics Push Is the Bigger Threat to Indian Pharma

While West Asia dominates headlines, China is quietly pulling ahead in biologics manufacturing. We dig into filings to see which Indian pharma companies are best prepared and which are falling behind.

BIOCONZYDUSLIFEALKEMPPLPHARMASUNPHARMAGLAND
Sector Insight 1 April 2026

Headline Says Tariff Pain for Textiles — The Real Winners Are in Electronics Manufacturing

US tariffs squeeze Indian garment exporters, but new trade deals with EU and UK are opening doors for electronics manufacturers and medical device makers. We dig into the filings.

CELEBRITYKPRMILLDIXONEPACKAMBERPOLYMED
Opportunity 31 March 2026

Oil Spikes on Hormuz Crisis — 5 Renewable Energy Stocks That Actually Benefit

As crude oil surges on Iran-Hormuz tensions and the Sensex crashes 1,700 points, renewable energy and solar stocks with strong order books stand to gain from accelerated energy transition.

PREMIERENESUZLONADANIGREENSWSOLARINOXWINDAJANTPHARMMRPL
Deep Dive 30 March 2026

Centre Eyes Essential Commodities Act for Bulk Drugs — Who Gets Hurt, Who Quietly Wins

The government is considering invoking the Essential Commodities Act to regulate bulk drug prices. We dig into filings to find which API makers face margin pressure and which formulation companies could benefit from cheaper inputs.

DIVISLABSOLARANEULANDLABSUNPHARMAAUROPHARMACIPLAGLAND
Impact Analysis 27 March 2026

West Asia Crisis Sends Crude Soaring — Five Companies Where the Pain Shows Up in Filings

The West Asia conflict is pushing crude oil higher. We dug into quarterly filings of IndiGo, HINDPETRO, BPCL, Asian Paints, and Oil India to see who gets hurt — and who quietly benefits.

INDIGOHINDPETROBPCLASIANPAINTOIL